Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon beta-1a in high-risk COVID-19 patients
2020-003872-42Phase 2Terminated
- Sponsor
- Istituto di Farmacologia Traslazionale
- Start
- Nov 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of interferon beta-1a in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Istituto di Farmacologia Traslazionale. Primary endpoint: Disease progression within 28 days. Started Nov 2020; status: terminated.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003872-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003872-42.